| Recruiting | Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or NCT07348302 | Inmunotek S.L. | Phase 3 |
| Completed | Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte NCT07427576 | Inmunotek S.L. | — |
| Completed | Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy. NCT06448585 | Gala Servicios Clinicos S.L. | Phase 4 |
| Completed | Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Stu NCT05960266 | University of Zurich | EARLY_Phase 1 |
| Completed | Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced NCT05540717 | Allergy Therapeutics | Phase 3 |
| Completed | A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment NCT05560698 | University of Aarhus | N/A |
| Recruiting | Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen NCT04891237 | Inmunotek S.L. | Phase 3 |
| Recruiting | Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. NCT04898283 | Inmunotek S.L. | Phase 3 |
| Recruiting | Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites NCT04435990 | Inmunotek S.L. | Phase 3 |
| Completed | Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environm NCT04583202 | Alyatec | N/A |
| Completed | Intervention in Chronic Pediatric Patients and Their Families. NCT04476433 | University of Valencia | N/A |
| Completed | Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rh NCT03821077 | Roxall Medicina España S.A | — |
| Completed | Red Maple Trials Cat Allergen Natural Exposure Chamber Validation in Cat-allergic Subjects NCT03414801 | Red Maple Trials Inc. | N/A |
| Completed | Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or All NCT02844842 | Roxall Medicina España S.A | — |
| Unknown | Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy NCT02661854 | Inmunotek S.L. | Phase 2 |
| Completed | Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy NCT02654223 | Inmunotek S.L. | Phase 2 |
| Completed | A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sen NCT02849210 | Roxall Medicina España S.A | Phase 1 |
| Completed | A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitiz NCT02477917 | Roxall Medicina España S.A | Phase 1 |
| Completed | Ragweed-SPIRE Follow-On Study NCT02396680 | Circassia Limited | — |
| Completed | Phase II HDM-SPIRE Safety and Efficacy Study NCT02150343 | Circassia Limited | Phase 2 |
| Completed | Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With A NCT02340130 | Laboratorios Leti, S.L. | Phase 2 |
| Completed | Grass Observational Study NCT02075138 | Circassia Limited | — |
| Completed | ToleroMune Grass Follow on Study NCT02292875 | Circassia Limited | — |
| Completed | ToleroMune House Dust Mite Follow on Study NCT01923792 | Circassia Limited | — |
| Completed | ToleroMune House Dust Mite (HDM) Tolerability Study NCT01949441 | Circassia Limited | Phase 2 |
| Completed | House Dust Mite Observational Study NCT01949428 | Circassia Limited | — |
| Completed | An Optional Investigation of Biomarkers of Efficacy NCT01949415 | Circassia Limited | — |
| Completed | Paediatric Safety Study in Cat-PAD NCT01921257 | Circassia Limited | Phase 2 |
| Completed | ToleroMune Grass Follow on Study NCT01923779 | Circassia Limited | — |
| Unknown | Ocular Allergy Treatment Practical Impact Trial NCT01808768 | Starx Research Center, LLC | Phase 4 |
| Completed | Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Par NCT01734265 | Laboratorios Leti, S.L. | Phase 2 |
| Completed | Phase III Cat-PAD Study NCT01620762 | Circassia Limited | Phase 3 |
| Completed | Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy NCT01720251 | Anergis | Phase 2 |
| Terminated | Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% De NCT01591343 | Laboratorios Leti, S.L. | Phase 2 |
| Completed | An Optional Two Year Follow Up Study to Study CP005A NCT01604018 | Circassia Limited | — |
| Completed | ToleroMune Ragweed Follow up Study NCT01448603 | Circassia Limited | — |
| Completed | ToleroMune House Dust Mites (HDM) Exposure Chamber Study NCT01447784 | Circassia Limited | Phase 2 |
| Completed | ToleroMune Grass Exposure Unit Study NCT01385800 | Circassia Limited | Phase 2 |
| Completed | Cat-PAD Follow on Study NCT01272323 | Circassia Limited | — |
| Completed | Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081) NCT00978029 | ALK-Abelló A/S | Phase 2 |
| Completed | 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma NCT01353755 | Allergopharma GmbH & Co. KG | Phase 3 |
| Completed | Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis NCT01013259 | Charite University, Berlin, Germany | Phase 2 |
| Completed | Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy NCT00800332 | Cytos Biotechnology AG | Phase 2 |
| Completed | Open Label Safety Study of a Birch Pollen Allergen Extract NCT00818181 | Allergopharma GmbH & Co. KG | Phase 2 |
| Completed | Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass NCT00671268 | Allergopharma GmbH & Co. KG | Phase 3 |
| Completed | Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) NCT00550550 | ALK-Abelló A/S | Phase 3 |
| Completed | Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) NCT00562159 | ALK-Abelló A/S | Phase 3 |
| Completed | PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the NCT00574210 | Faes Farma, S.A. | Phase 2 |
| Completed | Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT) NCT00537342 | Laboratorios Leti, S.L. | Phase 3 |
| Completed | Multicenter Trial of Immunotherapy With House Dust Mite Allergoid NCT00540631 | Allergopharma GmbH & Co. KG | Phase 3 |
| Completed | Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass NCT00457444 | University of Zurich | Phase 1 |